X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
X-linked adrenoleukodystrophy (X-ALD) is a fatal neurodegenerative disease caused by mutations in the ABCD1 gene, encoding a member of the peroxisomal ABC transporter family. The ABCD1 protein transports CoA-activated very long-chain fatty acids (VLCFAs) into peroxisomes for degradation via β-oxidation. In the severest form, X-ALD patients suffer from inflammatory demyelination of the brain. As the extent of the metabolic defect in the main immune cells is unknown, we explored their phenotypes concerning mRNA expression pattern of the three peroxisomal ABC transporters, VLCFA accumulation and peroxisomal β-oxidation. In controls, ABCD1 expression was high in monocytes, intermediate in B cells and low in T cells; ABCD2 expression was extremely low in monocytes, intermediate in B cells and highest in T cells; ABCD3 mRNA was equally distributed. In X-ALD patients, the expression patterns remained unaltered; accordingly, monocytes, which lack compensatory VLCFA transport by ABCD2, displayed the severest biochemical phenotype with a 6-fold accumulation of C26:0 and a striking 70% reduction in peroxisomal β-oxidation activity. In contrast, VLCFA metabolism was close to control values in B cells and T cells, supporting the hypothesis that sufficient ABCD2 is present to compensate for ABCD1 deficiency. Thus, the vulnerability of the main immune cell types is highly variable in X-ALD. Based on these results, we propose that in X-ALD the halt of inflammation after allogeneic hematopoietic stem cell transplantation relies particularly on the replacement of the monocyte lineage. Additionally, these findings support the concept that ABCD2 is a target for pharmacological induction as an alternative therapeutic strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the additive but not amplified severity of the metabolic and behavioural deficits might be partially explained by the rather complementary expression patterns of these two peroxisomal ABC transporters [41], [60], [62].”
From Abcd2 Is a Strong Modifier of the Metabolic Impairments in Peritoneal Macrophages of Abcd1-Deficient Mice (2014) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most likely candidate for mediating the residual β-oxidation activity (29%) for C26∶0 in the Abcd1/Abcd2 double-deficient MPMΦ is the third peroxisomal ABC transporter, ABCD3, in similarity to human X-ALD fibroblasts [7] and monocytes [41].”
From Abcd2 Is a Strong Modifier of the Metabolic Impairments in Peritoneal Macrophages of Abcd1-Deficient Mice (2014) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast to primary mouse peritoneal macrophages, primary human monocytes/macrophages virtually lack ABCD2 gene expression [40], [41].”
From Abcd2 Is a Strong Modifier of the Metabolic Impairments in Peritoneal Macrophages of Abcd1-Deficient Mice (2014) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“However, in contrast to human monocytes [41] or human fibroblasts [7], in the absence of ABCD1, sufficient amounts of endogenous ABCD2 are present to maintain a substantial β-oxidation capacity for VLCFA substrates (62% of wild-type β-oxidation activity for C26∶0, Fig. 5).”
From Abcd2 Is a Strong Modifier of the Metabolic Impairments in Peritoneal Macrophages of Abcd1-Deficient Mice (2014) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“In human monocytes/macrophages, ABCD2 is virtually not expressed [40] and, therefore, cannot compensate for the functional loss of ABCD1 resulting in a severe metabolic phenotype in this cell lineage of X-ALD patients [41].”
From Abcd2 Is a Strong Modifier of the Metabolic Impairments in Peritoneal Macrophages of Abcd1-Deficient Mice (2014) · cites this paper as [41]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statistics and Computing · doi:10.1007/978-0-387-21706-2 · Cited by 24,305
Simultaneous Inference in General Parametric Models
Hothorn, T., Bretz, F., & Westfall, P. (2008) · Biometrical Journal · doi:10.1002/bimj.200810425 · Cited by 13,847
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
nlme : Linear and nonlinear mixed effects models
DebRoy, S. (2006) · Medical Entomology and Zoology · Cited by 10,009
Mixed-Effects Models in S and S-PLUS
(2001) · Technometrics · doi:10.1198/tech.2001.s574 · Cited by 9,278
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508 · cited 1×
“Using this strategy, they cured the cerebral inflammation of two childhood CALD patients (15).”
BackgroundPutative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202 · cited 1×
“X-ALD is caused by mutations in the ABCD1 gene, which encodes the ABCD1 protein (formerly adrenoleukodystrophy protein, ALDP), constituting a half ATP-binding cassette (ABC)-transporter in the peroxisomal membrane (6).”
BackgroundMoser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Klucken, J., Büchler, C., Orsó, E., Kaminski, W. E., Porsch-Özcürümez, M., Liebisch, G., Kapinsky, M., Diederich, W., Drobnik, W., Dean, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.817 · Cited by 543
Adrenoleukodystrophy: A Clinical and Pathological Study of 17 Cases
Schaumburg, H. H. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490510033001 · Cited by 475
X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects
Kemp, S., Berger, J., & Aubourg, P. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.03.012 · Cited by 283 · cited 1×
“Heterozygous females often develop a milder form of AMN, but rarely adrenal insufficiency (,5%) or the devastating brain inflammation (1,3).”
BackgroundSelf-citationLangmann, T., Mauerer, R., Zahn, A., Moehle, C., Probst, M., Stremmel, W., & Schmitz, G. (2003) · Clinical Chemistry · doi:10.1373/49.2.230 · Cited by 259
Gene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy
Kemp, S., Wei, H.-M., Lu, J.-F., Braiterman, L. T., McGuinness, M. C., Moser, A. B., Watkins, P. A., & Smith, K. D. (1998) · Nature Medicine · doi:10.1038/3242 · Cited by 249
A HaemAtlas: characterizing gene expression in differentiated human blood cells
Watkins, N. A., Gusnanto, A., de Bono, B., De, S., Miranda-Saavedra, D., Hardie, D. L., Angenent, W. G. J., Attwood, A. P., Ellis, P. D., Erber, W., et al. (2009) · Blood · doi:10.1182/blood-2008-06-162958 · Cited by 242
Pathophysiology of X-linked adrenoleukodystrophy
Berger, J., Forss-Petter, S., & Eichler, F. S. (2014) · Biochimie · doi:10.1016/j.biochi.2013.11.023 · Cited by 238 · cited 3×
“Moreover, even within different phases during development of the cerebral inflammation and the ineffectiveness of anti-inflammatory therapies, different processes and cell types seem to be involved (10).”
BackgroundInfluentialSelf-citationThe human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl–CoA esters
van Roermund, C. W. T., Visser, W. F., IJlst, L., van Cruchten, A., Boek, M., Kulik, W., Waterham, H. R., & Wanders, R. J. A. (2008) · The FASEB Journal · doi:10.1096/fj.08-110866 · Cited by 233
Moser, H. W., Loes, D. J., Melhem, E. R., Raymond, G. V., Bezman, L., Cox, C. S., & Lu, S.-E. (2000) · Neuropediatrics · doi:10.1055/s-2000-9236 · Cited by 210
Pujol, A., Ferrer, I., Camps, C., Metzger, E., Hindelang, C., Callizot, N., Ruiz, M., Pàmpols, T., Giròs, M., & Mandel, J. L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh323 · Cited by 201 · cited 1×
“Functional overlap has been demonstrated in vitro in X-ALD fibroblasts (16) and in vivo in a mouse model of X-ALD (17), where overexpression of ABCD2 could compensate for ABCD1 deficiency.”
BackgroundX-linked adrenoleukodystrophy: Clinical, biochemical and pathogenetic aspects
Berger, J., & Gärtner, J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.07.010 · Cited by 199
Self-citationIs microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?
Eichler, F. S., Ren, J., Cossoy, M., Rietsch, A. M., Nagpal, S., Moser, A. B., Frosch, M. P., & Ransohoff, R. M. (2008) · Annals of Neurology · doi:10.1002/ana.21391 · Cited by 178
The role of ELOVL1 in very long-chain fatty acid homeostasis and X-linked adrenoleukodystrophy
Ofman, R., Dijkstra, I. M. E., van Roermund, C. W. T., Burger, N., Turkenburg, M., van Cruchten, A., van Engen, C. E., Wanders, R. J. A., & Kemp, S. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000061 · Cited by 170 · cited 1×
“They can be further elongated by enzymes of the ELOVL (elongation of VLCFAs) family and may be incorporated into different lipids such as phosphatidylcholine, gangliosides or sulphatides and lipoproteins (9).”
BackgroundCartier, N., & Aubourg, P. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00394.x · Cited by 151
Netik, A., Forss-Petter, S., Holzinger, A., Molzer, B., Unterrainer, G., & Berger, J. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.5.907 · Cited by 148
Self-citationWiesinger, C., Kunze, M., Regelsberger, G., Forss-Petter, S., & Berger, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.445445 · Cited by 145
Self-citationAdreno-leukodystrophy: Oxidative Stress of Mice and Men
Powers, J. M., Pei, Z., Heinzer, A. K., Deering, R., Moser, A. B., Moser, H. W., Watkins, P. A., & Smith, K. D. (2005) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000190064.28559.a4 · Cited by 129
Ito, M., Blumberg, B. M., Mock, D. J., Goodman, A. D., Moser, A. B., Moser, H. W., Smith, K. D., & Powers, J. M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.10.1004 · Cited by 125 · cited 2×
“Probably the antigen is presented by CD1 molecules on perivascular cells in an MHC class I independent manner leading to a further recruitment of proinflammatory cells (35).”
BackgroundBerger, J., Albet, S., Bentejac, M., Netik, A., Holzinger, A., Roscher, A. A., Bugaut, M., & Forss‐Petter, S. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00772.x · Cited by 106 · cited 1×
“Most likely, due to differing expression levels of the two genes in different cell types and tissues, endogenous ABCD2 cannot replace ABCD1 functionally (18,19).”
BackgroundSelf-citationValproic acid induces antioxidant effects in X-linked adrenoleukodystrophy
Fourcade, S., Ruiz, M., Guilera, C., Hahnen, E., Brichta, L., Naudi, A., Portero-Otín, M., Dacremont, G., Cartier, N., Wanders, R., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq082 · Cited by 100
Theda, C., Moser, A. B., Powers, J. M., & Moser, H. W. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90028-j · Cited by 99
Current and Future Pharmacological Treatment Strategies in X‐Linked Adrenoleukodystrophy
Berger, J., Pujol, A., Aubourg, P., & Forss‐Petter, S. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00393.x · Cited by 90
Self-citationHead trauma can initiate the onset of adreno-leukodystrophy
Raymond, G. V., Seidman, R., Monteith, T. S., Kolodny, E., Sathe, S., Mahmood, A., & Powers, J. M. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.11.005 · Cited by 90 · cited 1×
“Alternatively, traumatic brain injury could act as an extrinsic factor, promoting an opening of the blood–brain barrier initiating inflammation and demyelination (34).”
BackgroundPeroxisomal fatty acid β-oxidation in HepG2 cells
Watkins, P. A., Ferrell, E. V., Pedersen, J. I., & Hoefler, G. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90419-j · Cited by 86
Fatty Acid Composition of Human Myelin Proteolipid Protein in Peroxisomal Disorders
Bizzozero, O. A., Zuñiga, G., & Lees, M. B. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02003.x · Cited by 61
Weinhofer, I. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.22.2701 · Cited by 59
Self-citationLangmann, T., Mauerer, R., & Schmitz, G. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.059774 · Cited by 49
Oxidative Imbalance in Nonstimulated X-Adrenoleukodystrophy-Derived Lymphoblasts
Uto, T., Contreras, M. A., Gilg, A. G., & Singh, I. (2008) · Developmental Neuroscience · doi:10.1159/000191212 · Cited by 42
Lund, T. C., Stadem, P. S., Panoskaltsis-Mortari, A., Raymond, G., Miller, W. P., Tolar, J., & Orchard, P. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032218 · Cited by 41
Chitotriosidase as a biomarker of cerebral adrenoleukodystrophy
Orchard, P. J., Lund, T., Miller, W., Rothman, S. M., Raymond, G., Nascene, D., Basso, L., Cloyd, J., & Tolar, J. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-144 · Cited by 40
Hypoperfusion predicts lesion progression in cerebral X-linked adrenoleukodystrophy
Musolino, P. L., Rapalino, O., Caruso, P., Caviness, V. S., & Eichler, F. S. (2012) · Brain · doi:10.1093/brain/aws206 · Cited by 37
X-linked adrenoleukodystrophy phenotype is independent of ABCD2 genotype
Maier, E. M., Mayerhofer, P. U., Asheuer, M., Köhler, W., Rothe, M., Muntau, A. C., Roscher, A. A., Holzinger, A., Aubourg, P., & Berger, J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.09.092 · Cited by 34 · cited 1×
“No mutations have been found in the ABCD2 gene of X-ALD patients and genetic association studies indicated that ABCD2 is unlikely to be a genetic modifier locus (41).”
BackgroundSelf-citationX‐linked adrenoleukodystrophy mice demonstrate abnormalities in cholesterol metabolism
Weinhofer, I., Forss-Petter, S., Kunze, M., Žigman, M., & Berger, J. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.09.014 · Cited by 32
Self-citationCerebral X‐linked adrenoleukodystrophy in a girl with Xq27‐Ter deletion
Hershkovitz, E., Narkis, G., Shorer, Z., Moser, A. B., Watkins, P. A., Moser, H. W., & Manor, E. (2002) · Annals of Neurology · doi:10.1002/ana.10248 · Cited by 30
Yanagisawa, N., Shimada, K., Miyazaki, T., Kume, A., Kitamura, Y., Sumiyoshi, K., Kiyanagi, T., Iesaki, T., Inoue, N., & Daida, H. (2008) · Lipids in Health and Disease · doi:10.1186/1476-511x-7-48 · Cited by 29
Th 1 cytokine production by peripheral blood mononuclear cells in X-linked adrenoleukodystrophy
Biase, A. D., Merendino, N., Avellino, C., Cappa, M., & Salvati, S. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00469-x · Cited by 29
Lannuzel, A., Aubourg, P. R., & Tardieu, M. (1998) · European Journal of Paediatric Neurology · doi:10.1016/1090-3798(98)01002-7 · Cited by 26
Diagnosis of X-linked adrenoleukodystrophy in blood leukocytes
Unterberger, U., Regelsberger, G., Sundt, R., Bernheimer, H., & Voigtländer, T. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.04.015 · Cited by 11
Self-citationIsolation of Granulocytes: Which Transcriptome Do We Analyse – Neutrophils or Eosinophils?
Stejskal, S., Koutná, I., & Ručka, Z. (2010) · Folia Biologica · doi:10.14712/fb2010056060252 · Cited by 10
Research works printed but not linked: 1
- 2008, FASEB J OFF PUBL FED AM SOC EXP BIOL, 22, 4201
Cited by
Peroxisomes in brain development and function
Berger, J., Dorninger, F., Forss-Petter, S., & Kunze, M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.12.005 · Cited by 194
“Based on our recent observations, we have suggested that this is due to the intrinsic metabolic defect of macrophages and microglia in XALD; these cells cannot degrade VLCFA, which they have taken up by phagocytosing of myelin debris (particular rich in VLCFA in X-ALD), and then fail to support normal immunological br…”
BackgroundSelf-citationFatty acid metabolism in the progression and resolution of CNS disorders
Bogie, J. F. J., Haidar, M., Kooij, G., & Hendriks, J. J. A. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.01.004 · Cited by 167
Berger, J., Wiesinger, C., & Eichler, F. (2015) · The Application of Clinical Genetics · doi:10.2147/tacg.s49590 · Cited by 140
Self-citationPeroxisomes in Immune Response and Inflammation
Di Cara, F., Andreoletti, P., Trompier, D., Vejux, A., Bülow, M. H., Sellin, J., Lizard, G., Cherkaoui-Malki, M., & Savary, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163877 · Cited by 128
Bergner, C. G., van der Meer, F., Winkler, A., Wrzos, C., Türkmen, M., Valizada, E., Fitzner, D., Hametner, S., Hartmann, C., Pfeifenbring, S., et al. (2019) · Glia · doi:10.1002/glia.23598 · Cited by 94
“Recently it has been shown in X-ALD that monocytes/macrophages are the metabolically most affected peripheral immune cell type (Weber et al., 2014) and that switches to an anti-inflammatory M2 phenotype after activation are impaired (Weinhofer et al.”
Background
Metadata
- Authors
- Weber, F. D., Wiesinger, C., Forss-Petter, S., Regelsberger, G., Einwich, A., Weber, W. H. A., Kohler, W., Stockinger, H., & Berger, J.
- Affiliations
- Medical University of Vienna (AT)
- Corresponding author
- Berger, J.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-12-20
- Volume
- 23
- Issue
- 10
- Pages
- 2542-2550
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC3990157
- OpenAlex
- W2111369450
- Cited by
- 63
- References
- 47
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 8 · 2023: 7 · 2022: 6 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 7 · 2017: 4 · 2015: 9 · 2014: 5
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Human Molecular Genetics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Commission (241622)
- Austrian Science Fund (P26112-B19,)
- Association Européenne contre les Leucodystrophies
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- X-linked adrenoleukodystrophy, ABCD1, ABCD2, ABCD3, very long chain fatty acids, peroxisomal ABC transporters, monocytes, lymphocytes, peroxisomal beta-oxidation, gene expression, demyelination, allogeneic hematopoietic stem cell transplantation
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily D, ATP Binding Cassette Transporter, Subfamily D, Member 1, Adrenoleukodystrophy, Adult, Cells, Cultured, Fatty Acids, Humans, Lymphocytes, Male, Middle Aged, Monocytes, Oxidation-Reduction, Gene Expression, Case-Control Studies, ATP-Binding Cassette Transporters, Peroxisomes, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.